341 related articles for article (PubMed ID: 11936424)
1. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
Zheng Y; Shirato I; Maeda A; Kobayashi N; Liao J; Shou I; Fukui M; Tomino Y
J Nephrol; 2002; 15(1):36-41. PubMed ID: 11936424
[TBL] [Abstract][Full Text] [Related]
2. Effect of captopril on chronic puromycin aminonucleoside nephrosis in rats.
Radin MJ; Wilke WL; Fettman MJ
Res Commun Chem Pathol Pharmacol; 1986 Nov; 54(2):279-82. PubMed ID: 3538253
[TBL] [Abstract][Full Text] [Related]
3. Effect of a low-protein diet on expression of non-muscle type myosin heavy-chain isoforms in glomeruli of rats with puromycin aminonucleoside nephrosis.
Koide H; Nakamura T; Kimura K; Ebihara I; Nagai R; Tomino Y
Nephrol Dial Transplant; 1996 Sep; 11(9):1769-74. PubMed ID: 8918620
[TBL] [Abstract][Full Text] [Related]
4. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Zoja C; Corna D; Bruzzi I; Foglieni C; Bertani T; Remuzzi G; Benigni A
Exp Nephrol; 1996; 4(4):213-21. PubMed ID: 8983642
[TBL] [Abstract][Full Text] [Related]
5. Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
Marinides GN; Groggel GC; Cohen AH; Cook T; Baranowski RL; Westenfelder C; Border WA
Am J Pathol; 1987 Nov; 129(2):394-401. PubMed ID: 2823616
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
[TBL] [Abstract][Full Text] [Related]
7. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside.
Grond J; Weening JJ; Elema JD
Lab Invest; 1984 Sep; 51(3):277-85. PubMed ID: 6471809
[TBL] [Abstract][Full Text] [Related]
8. Ameliorative effects of dietary protein restriction in chronic aminonucleoside nephrosis.
Diamond JR; Karnovsky MJ
J Lab Clin Med; 1987 May; 109(5):538-44. PubMed ID: 3572200
[TBL] [Abstract][Full Text] [Related]
9. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
Ebihara I; Nakamura T; Tomino Y; Koide H
Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
[TBL] [Abstract][Full Text] [Related]
10. Glomerular epithelial detachment, not reduced charge density, correlates with proteinuria in adriamycin and puromycin nephrosis.
Whiteside C; Prutis K; Cameron R; Thompson J
Lab Invest; 1989 Dec; 61(6):650-60. PubMed ID: 2601299
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis.
Hjalmarsson C; Lidell ME; Haraldsson B
Nephrol Dial Transplant; 2006 May; 21(5):1223-30. PubMed ID: 16410268
[TBL] [Abstract][Full Text] [Related]
12. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.
Nabokov A; Amann K; Wagner J; Gehlen F; Münter K; Ritz E
Nephrol Dial Transplant; 1996 Mar; 11(3):514-20. PubMed ID: 8671823
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis.
Nakayama K; Natori Y; Sato T; Kimura T; Sugiura A; Sato H; Saito T; Ito S; Natori Y
J Lab Clin Med; 2004 Feb; 143(2):106-14. PubMed ID: 14966466
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glomerular visceral epithelial cell endocytosis during nephrosis induced by puromycin aminonucleoside.
Schwartz MM; Sharon Z; Pauli BU; Lewis EJ
Lab Invest; 1984 Dec; 51(6):690-6. PubMed ID: 6389977
[TBL] [Abstract][Full Text] [Related]
15. Significant suppressive effect of low-dose temocapril, an ACE inhibitor with biliary excretion, on FGS lesions in hypertensive rats.
Suyama K; Muso E; Yashiro M; Sasayama S
Nephron; 2000 Dec; 86(4):491-8. PubMed ID: 11124599
[TBL] [Abstract][Full Text] [Related]
16. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
[TBL] [Abstract][Full Text] [Related]
17. Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats.
Shinosaki T; Takagawa I; Sunagawa N; Yonetani Y; Kurihara H
Jpn J Pharmacol; 1997 Apr; 73(4):337-45. PubMed ID: 9165371
[TBL] [Abstract][Full Text] [Related]
18. Adverse effect of indomethacin in experimental chronic nephrosis.
Kleinknecht C; Laouari D; Gubler MC; Gros F
Int J Pediatr Nephrol; 1983 Jun; 4(2):83-8. PubMed ID: 6618773
[TBL] [Abstract][Full Text] [Related]
19. Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.
Kim BS; Park HC; Kang SW; Choi KH; Ha SK; Han DS; Lee HY
Yonsei Med J; 2005 Feb; 46(1):141-8. PubMed ID: 15744817
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
